Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK/PD and Safety of UI058 vs UIC202004 in Healthy Subjects
NCT05282914Phase 1Completed
- Sponsor
- Korea United Pharm Inc.
- Start
- Feb 2021
- Primary completion
- Apr 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of rabeprazole in gastroesophageal reflux disease (GERD) (2 arms), sponsored by Korea United Pharm Inc. Primary endpoints: Area under the plasma drug concentration-time curve within a dosing interval at steady state and Percent change from baseline in integrated gastric acidity at Day 7. Started Feb 2021; status: completed.
02
Drugs
rabeprazole
03
Conditions
gastroesophageal reflux disease (GERD)
Beyond the preview
Go deeper on NCT05282914.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05282914.